BACKGROUND: Live oral cholera vaccines may protect against cholera in a manner similar to natural cholera infections. However, information on which to base these vaccines is limited. METHODS: The study was conducted in a cholera-endemic population in Bangladesh. Patients with cholera (index patients) detected between 1991 and 2000 were age-matched to 4 cholera-free controls and then followed up during the subsequent 3 years. RESULTS: El Tor cholera was associated with a 65% (95% confidence interval [CI], 37%-81%; P < .001) lower risk of a subsequent El Tor episode. Reduction of the risk of subsequent El Tor cholera was similar for children < 5 years and for older persons and was sustained during all 3 years of follow-up. Having El Tor Inaba cholera was associated with lower risks of both El Tor Inaba and El Tor Ogawa cholera, but having El Tor Ogawa cholera was associated only with a reduced risk of El Tor Ogawa cholera. O139 cholera was associated with a 63% (95% CI, -61% to 92%; P = .18) lower risk of subsequent O139 cholera, but there was no evidence of cross-protection between the O1 and O139 serogroups. CONCLUSIONS: Live oral cholera vaccines designed to protect against the O1 and O139 serogroups should contain at least the Inaba serotype and strains of both serogroups.
BACKGROUND: Live oral cholera vaccines may protect against cholera in a manner similar to natural cholera infections. However, information on which to base these vaccines is limited. METHODS: The study was conducted in a cholera-endemic population in Bangladesh. Patients with cholera (index patients) detected between 1991 and 2000 were age-matched to 4 cholera-free controls and then followed up during the subsequent 3 years. RESULTS: El Tor cholera was associated with a 65% (95% confidence interval [CI], 37%-81%; P < .001) lower risk of a subsequent El Tor episode. Reduction of the risk of subsequent El Tor cholera was similar for children < 5 years and for older persons and was sustained during all 3 years of follow-up. Having El Tor Inaba cholera was associated with lower risks of both El Tor Inaba and El Tor Ogawa cholera, but having El Tor Ogawa cholera was associated only with a reduced risk of El Tor Ogawa cholera. O139 cholera was associated with a 63% (95% CI, -61% to 92%; P = .18) lower risk of subsequent O139 cholera, but there was no evidence of cross-protection between the O1 and O139 serogroups. CONCLUSIONS: Live oral cholera vaccines designed to protect against the O1 and O139 serogroups should contain at least the Inaba serotype and strains of both serogroups.
Authors: J D Clemens; F van Loon; D A Sack; M R Rao; F Ahmed; J ChakrabortY; B A Kay; M R Khan; M D Yunus; J R Harris Journal: Lancet Date: 1991-04-13 Impact factor: 79.321
Authors: W H Mosley; W M McCormack; M Fahimuddin; K M Aziz; A S Rahman; A K Chowdhury; A R Martin; J C Feeley; R A Phillips Journal: Bull World Health Organ Date: 1969 Impact factor: 9.408
Authors: J D Clemens; D A Sack; J R Harris; J Chakraborty; M R Khan; B F Stanton; B A Kay; M U Khan; M Yunus; W Atkinson Journal: Lancet Date: 1986-07-19 Impact factor: 79.321
Authors: Daniel T Leung; Mohammad Arif Rahman; M Mohasin; Sweta M Patel; Amena Aktar; Farhana Khanam; Taher Uddin; M Asrafuzzaman Riyadh; Amit Saha; Mohammad Murshid Alam; Fahima Chowdhury; Ashraful Islam Khan; Richelle Charles; Regina LaRocque; Jason B Harris; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan Journal: Clin Vaccine Immunol Date: 2012-03-21
Authors: Ana A Weil; Fahima Chowdhury; Ashraful I Khan; Daniel T Leung; Taher Uddin; Yasmin Ara Begum; Nirod Chandra Saha; Richelle C Charles; Regina C Larocque; Jason B Harris; Edward T Ryan; Firdausi Qadri; Stephen B Calderwood Journal: Am J Trop Med Hyg Date: 2012-09-10 Impact factor: 2.345
Authors: Taher Uddin; Amena Aktar; Peng Xu; Russell A Johnson; M Arifur Rahman; Daniel T Leung; Sadia Afrin; Aklima Akter; Mohammad Murshid Alam; Atiqur Rahman; Fahima Chowdhury; Ashraful I Khan; Taufiqur Rahman Bhuiyan; Meagan K Bufano; Rasheduzzaman Rashu; Yanan Yu; Ying Wu-Freeman; Jason B Harris; Regina C LaRocque; Richelle C Charles; Pavol Kováč; Stephen B Calderwood; Edward T Ryan; Firdausi Qadri Journal: Am J Trop Med Hyg Date: 2014-03-31 Impact factor: 2.345
Authors: Andrea Rinaldo; Enrico Bertuzzo; Lorenzo Mari; Lorenzo Righetto; Melanie Blokesch; Marino Gatto; Renato Casagrandi; Megan Murray; Silvan M Vesenbeckh; Ignacio Rodriguez-Iturbe Journal: Proc Natl Acad Sci U S A Date: 2012-04-13 Impact factor: 11.205
Authors: Russell A Johnson; Taher Uddin; Amena Aktar; M Mohasin; Mohammad Murshid Alam; Fahima Chowdhury; Jason B Harris; Regina C LaRocque; Meagan Kelly Bufano; Yanan Yu; Ying Wu-Freeman; Daniel T Leung; David Sarracino; Bryan Krastins; Richelle C Charles; Peng Xu; Pavol Kovác; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan Journal: Clin Vaccine Immunol Date: 2012-09-19
Authors: Brandon Sit; Bolutife Fakoya; Ting Zhang; Gabriel Billings; Matthew K Waldor Journal: Proc Natl Acad Sci U S A Date: 2021-02-16 Impact factor: 11.205